Nexalin Technology, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NXL | AMIX | NMTC | STIM | NUWE | SINT | |
|---|---|---|---|---|---|---|
| Market cap | 3.52M | 6.08M | 9.79M | 162.30M | 2.44M | 14.20M |
| P/E (TTM) | — | — | — | — | 0.0 | — |
| Forward P/E | -0.4 | -0.4 | -3.8 | -6.3 | -0.3 | -2.0 |
| Price/book | 1.6 | 0.5 | 2.5 | 9.1 | -0.2 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −91.32% | −87.05% | −80.25% | −26.30% | −99.45% | −49.41% |
| Today | −7.44% | −0.32% | −4.02% | 0.00% | −2.71% | +0.95% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All NXL news ›Nexalin Technology notifies Nasdaq compliance on minimum bid price
Nexalin Technology (NXL) regains Nasdaq $1 bid price compliance after reverse split; learn what’s next as it must meet equity rules by Jan 4, 2027—read now. Nexalin Technology (NXL) announced Thursday that it has received written…
Nexalin Technology Stock Surges 71%
Nexalin Technology is making serious waves in the market with a stunning 71.26% surge that's catching investors' attention. The dramatic jump puts the stock firmly in the trending category as traders scramble to understand what's driving…
NXL Stock Pops As Nexalin Technology Hires Global Commercial Advisor
Nexalin Technology Inc. surged as pivotal mental-health treatment developments lifted sentiment, and stocks have been trading up by 66.36 percent. Nexalin Technology Inc. is a classic high-risk, high-reward small-cap story, and the numbers…
Nexalin Technology shares surge on South America commercialization and manufacturing deal | NXL Stock News
Nexalin Technology shares surge on South America commercialization and manufacturing deal Quiver Quantitative Nexalin Technology shares surge on South America commercialization and manufacturing deal Nexalin Technology (NXL) is up 73.6%…
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
Appointment as Senior Strategic Advisor marks the Company’s expansion from clinical development toward commercialization of its DIFS™ platform in the United States, Europe and South America DiTota spent over two decades in neuromodulation…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
headlinesplus.com1
-
manilatimes.net1
-
quiverquant.com1
-
seekingalpha.com1
-
stockstotrade.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.